RECENT NEWS
For Media Inquiries
Alisa Santiesteban, Director of Marketing & Communications
970-926-1277 / Alisa@CanDo-MS.org
Media Kit
Can Do Multiple Sclerosis Announced as Benefactor for 11th Annual Man of the Cliff
September 25th, 2019
Man of the Cliff Returns to Avon's Nottingham Park October 12-13, 2019: Announces Can Do Multiple Sclerosis as Benefactor for 11th Annual Event
Continue ReadingWhat’s Top of Mind for People with Multiple Sclerosis?
September 15th, 2019
New Research from Can Do MS and EMD Serono Identifies Financial Planning and Staying in the Workplace as Critical Concerns in Managing Unpredictable Disease
Continue Reading
Support Can Do MS by buying Super Rad Raygun this month
September 6th, 2019
Independent game developers Chris Bryant and Chris Hernandez are raising money for families living with MS. All revenue for Super Rad Raygun on itch.io during the month of September will be donated to Can Do MS!
Continue Reading
This September, show the world how you #KickMS to inspire others and spread awareness of multiple sclerosis
September 3rd, 2019
Can Do Multiple Sclerosis launched their annual, online campaign that encourages people living with MS, as well as their friends and supporters, to share how they thrive with MS during September’s Can Do Month celebration.
Continue Reading
Pro Cyclist Tyler Hamilton’s Annual MS Global Bike Tour Comes to Nova Scotia to Raise Funds for Multiple Sclerosis
August 16th, 2019
MS Global 2019, a seven-day annual charitable bicycle tour founded by former professional cyclist Tyler Hamilton to raise funds for families with multiple sclerosis (MS), will be held in Cape Breton Island, Nova Scotia from Sept. 14 to Sept. 22.
Continue Reading
FDA approves new oral drug to treat multiple sclerosis
April 2nd, 2019
The U.S. Food and Drug Administration approved Mayzent (siponimod) tablets to treat adults with relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
Continue Reading
FDA Approves MAVENCLAD® (Cladribine) Tablets as First and Only Short-Course Oral Treatment for Relapsing-Remitting and Active Secondary Progressive Multiple Sclerosis
April 2nd, 2019
EMD Serono announced that the U.S. Food and Drug Administration has approved MAVENCLAD® (cladribine) tablets for the treatment of adults with relapsing-remitting disease and active secondary progressive disease.
Continue Reading
Lokai Launches Multiple Sclerosis Teal Bracelet
March 4th, 2019
Lokai, the socially responsible brand representing the importance of finding balance along life’s journey, announced a new teal bracelet in partnership with Can Do Multiple Sclerosis (Can Do MS).
FDA Accepts BrainStorm’s NurOwn® IND Application for Progressive Multiple Sclerosis
December 17th, 2018
BrainStorm Cell Therapeutics Inc. announced that the U.S. Food and Drug Administration has accepted the Investigational New Drug (IND) application to initiate a Phase 2 clinical trial of NurOwn® for the treatment of progressive multiple sclerosis.
Continue Reading
Alkermes and Biogen Announce Submission of a New Drug Application to U.S. Food and Drug Administration for Diroximel Fumarate in Multiple Sclerosis
December 17th, 2018
Diroximel fumarate was designed to provide patients with relapsing forms of multiple sclerosis a novel oral fumarate with a differentiated profile. The data encompassed in the regulatory package underscore diroximel fumarate’s potential to be a meaningful, new treatment option for the MS community.
Continue Reading